Viking Therapeutics Inc (USD)
VKTX
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range6.46 | 6.84
52-Wk Range- | -
Last Close6.84
Mkt Cap (m)497.67
Dividend yield-
ISINUS92686J1060
Volume3,025,776.00
Exchange VenueNAS

Company Profile

Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.

Key Information
Price/Earning-
Price/Book1.90
Price/Sales-
P/CF-
Rev Growth (3 year avg)0.00
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-8.97
Debt/Equity0.00

Documents

Prospectus
en 02/08/2019
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

http://www.vikingtherapeutics.com

Financials

Income Statement
USD201420152016201720182019
Revenue (m)0.000.000.000.000.000.00
Operating Income (m)-23.47-12.00-13.85-19.07-26.16-32.69
Net Income (m)-21.88-23.40-14.73-20.58-22.06-25.78
Basic EPS-7.03-3.68-0.90-0.79-0.38-0.36
Avg. Diluted Shares Outstanding (m)4.316.3616.2825.9857.5871.96
Balance Sheet
USD201420152016201720182019
Current Assets (m)0.7715.2013.9721.85302.13283.50
Non Current Assets (m)2.270.240.560.270.180.76
Total Assets (m)3.0415.4414.5422.12302.31284.26
Current Liabilities (m)22.521.986.488.664.556.78
Total Liabilities (m)------
Total Equity (m)-22.138.728.0413.46297.75277.12
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)-1.59-8.73-11.07-14.76-18.76-24.75
Capital Expenditure (m)------
Figures are quoted in USD unless stated otherwise
-
No change
$
6.84
Last Price